134 related articles for article (PubMed ID: 1871829)
21. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
Bass EB; Powe NR; Goodman SN; Graziano SL; Griffiths RI; Kickler TS; Wingard JR
Bone Marrow Transplant; 1993 Sep; 12(3):273-82. PubMed ID: 8241987
[TBL] [Abstract][Full Text] [Related]
22. Current approaches to management of infections in bone marrow transplants.
Winston DJ; Ho WG; Champlin RE
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S25-35. PubMed ID: 2693107
[TBL] [Abstract][Full Text] [Related]
23. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
24. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
[TBL] [Abstract][Full Text] [Related]
25. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
26. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
27. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation.
Hiemenz JW; Greene JN
Hematol Oncol Clin North Am; 1993 Oct; 7(5):961-1002. PubMed ID: 8226568
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic bone marrow transplantation: procedures and complications.
Parr MD; Messino MJ; McIntyre W
Am J Hosp Pharm; 1991 Jan; 48(1):127-37. PubMed ID: 2000873
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation: the City of Hope experience.
Smith EP; Nademanee A
Clin Transpl; 1995; ():291-310. PubMed ID: 8794275
[TBL] [Abstract][Full Text] [Related]
30. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
31. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
Yee GC; McGuire TR
Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
[TBL] [Abstract][Full Text] [Related]
33. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
34. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
35. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
37. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
38. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G
Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664
[TBL] [Abstract][Full Text] [Related]
40. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]